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Abstract: Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inﬂ  ammatory skin 
disease. AD long-term treatment is usually required to control and prevent ﬂ  ares, and patients 
need a treatment that is safe and efﬁ  cacious when applied continuously or intermittently over 
a prolonged period of time. The treatment options should be chosen according to age, clinical 
features and severity of the disease in every single patient. For the treatment of a chronic disease 
like AD, sustained tolerability and efﬁ  cacy of the applied medications are essential. A topical 
immunomodulator, tacrolimus ointment, provides an alternative to topical corticosteroids without 
the associated adverse events. Tacrolimus is a macrolide lactone with unique immunomodula-
tory properties and strong anti-inﬂ  ammatory activities and can be used without increasing the 
risk of infection or other non-application site adverse events, and without loss of effectiveness, 
in patients with AD.
Keywords: atopic dermatitis, tacrolimus, safety
Atopic dermatitis: general aspects
Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic inﬂ  ammatory skin 
disease that is particularly prevalent in the pediatric population, as 60% of the cases 
are diagnosed under the age of 1 year.1
It is the most common chronic disease of childhood and its incidence has been 
increasing during the recent decades in Western countries. The prevalence of AD is 
10% to 20% in children and 1% to 3% in adults in temperate developed countries.2 
AD has a chronic or chronically relapsing course with remissions and exacerbations 
of variable length. Typical clinical features include multiple lesions with erythema, 
excoriation, erosions accompanied by a serous exudate, accentuated skin markings 
(licheniﬁ  cation), ﬁ  brotic papules, severely dry skin, and a susceptibility to cutaneous 
infections.3 The main symptom is intense itching and excessive scratching can cause 
further damage such as excoriation, erosions and infections.4 The lesions have a typical 
age-dependent distribution pattern. In infants, nummular or seborrhoeic type eczema 
occurs on the cheeks, chin and trunk. In 1- to 4-year-old children, affected areas include 
extensor and sometimes ﬂ  exural sides of the extremities, the hands, face, neck and 
perioral area. In 4- to 16-year-old children, ﬂ  exural eczema predominates, with face, 
hands, feet and gluteal area affected. In adults, eczema most often occurs on the face, 
neck, upper body and extremities.5 AD is a clinical diagnosis. Haniﬁ  n and Rajka were 
the ﬁ  rst to develop a diagnosis of this disease based on deﬁ  ned criteria,6 as described in 
Table 1. The histopathology is quite typical for any type of eczema with a superﬁ  cial 
perivascular inﬂ  ammatory inﬁ  ltrate consisting mainly of T lymphocytes.7 The etiology 
of AD is unknown, but it is thought that a genetic presposition exists with symptoms 
being triggered by various external and psychological factors.8
The genetic predisposition is strong. Its parental inheritance9 is complex and 
includes multiple gene interactions and environmental inﬂ  uences. AD, asthma Clinical, Cosmetic and Investigational Dermatology 2009:2 2
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and elevated serum IgE have been linked to almost every 
chromosome, but no single gene can be implicated as the 
gene for the development of the skin disease.10
This hyper-IgE condition leads to a group of atopy-related 
diseases in many AD patients, such as asthma and allergic 
rhinitis, bronchial hyper-responsiveness and eosinophilic 
airway inﬂ  ammation, atopic blepharoconjunctivitis.8–9
Pathophysiology of AD is characterized by dysregulated 
immune responses that consist of an increased systemic Th2 
response and a combination of Th2 and Th1 responses in the 
skin lesions.11 Recent studies highlight the role of antigen-
speciﬁ  c effector T-lymphocytes and down-regulatory CD4+ 
T-cells (Treg). These cells are responsible for the cutaneous 
inﬂ  ammatory response through the production of inﬂ  ammatory 
cytokines and the destruction of keratinocytes by apoptosis.12
Moreover in AD patients skin barrier function is deeply 
altered. Peptides with a molecular mass over 500 Da do not 
penetrate healthy normal skin, whereas in AD, environ-
mental allergens of up to 20 kDa may penetrate the skin. 
This makes the skin susceptible to environmental factors 
such as detergents, irritants, allergens, microbial toxins, 
and physical or psychological stress.13 Defects of epidermal 
differentiation such as altered ﬁ  laggrin expression weaken 
the epidermal barrier and predispose patients with AD to 
epicutaneous allergic sensitization as well as to physical, 
microbial and irritant skin damage. This barrier damage 
activates keratinocytes to produce inﬂ  ammatory cytokines 
and starts the inﬂ  ammatory cycle leading to T-cell activation, 
IgE-production and clinical AD.14
About 70% to 80% of patients with AD are considered 
to have classical, ie, IgE-associated or allergic, AD because 
they show elevated serum-IgE levels or positive skin prick 
test results for aeroallergens or food allergens, whereas the 
remaining 20% to 30% never show this kind of IgE-mediated 
sensitization and are considered to have non-IgE-associated 
or non-allergic AD.15
IgE-mediated sensitization may not yet be evident in 
infants or young children but it develops with increasing age. 
As the skin barrier function in AD is weakened, and the skin 
is deﬁ  cient in antimicrobial peptides such as defensins and 
cathelisins, various microbes are able to colonize the skin and 
cause secondary infections. The clinically relevant microbes 
in AD are Staphylococcus aureus, herpes simplex virus 
(HSV), and Malassezia (formerly known as Pityrosporum) 
yeast species.13
AD can signiﬁ  cantly affect the child’s quality of life as 
patients are often distressed by their appearance, have low 
self-esteem and sometimes cannot enjoy normal routine 
activities and social interactions.4
Treatment options in AD
AD tends to be a chronic disease with a relapsing course 
so that long-term treatment is usually required to control 
and prevent ﬂ  ares. Patients need a treatment that is safe and 
efﬁ  cacious when applied continuously or intermittently over 
a prolonged period of time. The treatment options should be 
chosen according to age, clinical features and severity of the 
disease in every single patient.
Topical glucocorticosteroids (corticosteroids) have been 
the mainstay of AD treatment for the past few decades. They 
relieve the symptoms and inﬂ  ammation of AD quickly but are 
ofﬁ  cially indicated only for short-term use, usually for only 
1 to 3 weeks. In long-term use of the compounds cutaneous 
side-effects are common, and include skin atrophy, bruising, 
telangiectasies, striae, steroid acne, hypertrichosis, tachy-
phylaxis, increased treatment tolerance (steroid resistance), 
and worsening of underlying secondary infections. Topical 
corticosteroids for treatment of eyelid and facial eczema 
may increase intraocular pressure and induce glaucoma and 
cataracts.16
Antihistamines are widely used for patients with AD, 
especially if allergic rhinoconjunctivitis and allergic asthma 
are co-existent. First-generation compounds such as hydroxy-
zine are useful for nocturnal pruritus due to their sedative 
effect. They do not seem to work on pruritus itself because, 
Table 1 The Haniﬁ  n and Rajka criteria: shortened list
Major criteria Pruritus
Early age of onset
Typical morphology and distribution; 
ﬂ  exural licheniﬁ  cation and linearity 
in adults; facial and extensor involve-
ment during infancy and childhood
Chronic or chronically relapsing 
dermatitis
Personal or family history of atopy 
(asthma, allergic rhinoconjunctivitis, 
atopic dermatitis)
Minor or less 
speciﬁ  c criteria
Xerosis
Ichthyosis
Palmar hyperlinearity
Keratosis pilaris
Immediate skin response
Hand/foot dermatitis
Cheilitis
Nipple eczema
Susceptibility to cutaneous infections 
(especially Staphylococcus aureus and 
herpes simplex)
Perifollicular accentuationClinical, Cosmetic and Investigational Dermatology 2009:2 3
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unlike in urticaria, histamine is not considered to be a major 
pruritogen in AD.16,17
Commonly it is possible to manage AD with topical 
treatments or in association with antihistamines, but, on 
the other hand, severe AD that does not respond adequately 
to topical treatment often requires the addition of systemic 
long-term immunomodulator treatment.14
Systemic glucocorticosteroids such as prednisone, 
prednisolone and methylprednisolone often serve as rescue 
therapy in severe AD exacerbations. They relieve itch and 
inﬂ  ammation quickly, but the risk for AD relapse soon 
after cessation of treatment is high. In addition to having 
the same side-effects as topical corticosteroids, they may 
cause arterial hypertension, electrolyte imbalance, impaired 
glucose metabolism, Cushing’s syndrome, and osteoporosis, 
especially in long-term treatment.16–18
Cyclosporine (cyclosporine A) is a non-myelosuppressive 
immunosuppressant, extensively studied in AD, and has shown 
good efﬁ  cacy in adults and children. It acts by downregulating 
and inhibiting the cytokine production of Th2 cells. Treatment 
of AD with cyclosporine requires a regular follow-up by a der-
matologist owing to its possible adverse effects: arterial hyper-
tension, nephrotoxicity, immunosuppression and oncogenetic 
potential. The usual initial dose is 2.0 to 5.0 mg/kg, which 
should be tapered down to the lowest effective dose.19,20
Azathioprine is an old compound used for similar indica-
tions as for cyclosporine. Adverse effects include bone mar-
row suppression and increased oncogenic risk. At present, the 
long-term effects of azathioprine in AD are unknown.20
Methotrexate is another old drug compound used similarly 
to azathioprine. Its main adverse effects include liver toxic-
ity, anemia, thrombopenia, gastrointestinal dysfunction and 
pneumonitis.20 Other newer treatment modalities tried for 
severe treatment-resistant AD include mycophenolate mofetil, 
interferon gamma (IFN-γ), intravenous immunoglobulin 
(IVIG) and the new TNF-α inhibitors or “biologic” treatments 
designed for rheumatoid arthritis and psoriasis20 (Table 2).
However, all these therapeutical options will diminish 
but not eliminate the need for topical treatments, so that they 
are considered as secondary treatments of AD, combined 
with topical corticosteroids when these are not sufﬁ  cient to 
control the disease. They may diminish the need for topical 
corticosteroids but do not replace them.21
Several types of ultraviolet (UV) light therapy can be 
associated with topical treatment: UVB, narrow-band UVB 
(311–313 nm), UVA (320–400 nm) and PUVA (UVA 
usually with topical photosensitizing psoralens). Adverse 
effects include skin erythema, which is less with UVB 
treatment, skin burning and risk for skin malignancies with 
cumulative UV dose.22
For the treatment of a chronic disease like AD, sustained 
tolerability and efﬁ  cacy of the applied medications are 
essential. A topical immunomodulator, tacrolimus ointment, 
provides an alternative to topical corticosteroids without the 
associated adverse events.
Mechanism of action of tacrolimus
Tacrolimus ointment is a topical calcineurin inhibitor (TCI) 
and was the ﬁ  rst of this class of topical preparations to be 
developed particularly for the treatment of AD.23
Tacrolimus is a macrolide lactone with unique immu-
nomodulatory properties and was originally isolated in 
Japan in 1980 from the fungus-like bacterium Streptomyces 
tsukubaensis. It was ﬁ  rst approved for the treatment of AD 
in Japan in 1999, with approvals following for the USA in 
2000 and for The European Union in 2002.24–26
Tacrolimus is absorbed passively into skin, particularly 
in affected skin, and reduces skin inﬂ  ammation and pru-
ritus in AD, blocking T-cells activation by binding to the 
cytosolic immunophilin receptor (macrophilin-12) to form a 
complex that inhibits the activity of the enzyme calcineurin. 
Calcineurin normally dephosphorylates a cytosolic transcription 
factor, the nuclear factor of activated T-cell protein (NF-ATp), 
allowing it to travel to the nucleus, where it initiates the activa-
tion of a variety of genes involved in T-cell activation.25,27
Because this transcription factor is essential for the 
production of IL-2 and other cytokines (INF-gamma, IL-3, IL-4, 
IL-5), prevention of its translocation effectively inhibits Th1-cell 
and Th2-cell activation. Calcineurin inhibition can also decrease 
production of both the proinflammatory cytokines, tumor 
necrosis factor and granulocyte-macrophage colony-stimulating 
factor, necessary for the maturation of dendritic cells.28–31
Tacrolimus effects on the immune system (including 
antigen-presenting cells [APC] T-lymphocytes, mast cells 
and keratinocytes) are well studied. In AD pathogenesis, APC 
are involved: CD1a+ epidermal APC are more represented 
in untreated lesions of the disease, but it has been demon-
strated that treatment with topical tacrolimus reduces CD1a+ 
expression.25,32,33 Several in vivo animal studies conﬁ  rm that 
tacrolimus can inhibit the effective phase of contact hyper-
sensitivity (in mice) and partially the sensitization phase of 
contact hypersensitivity.
Moreover further studies have demonstrated that in vivo 
keratinocyte apoptosis induced by activated T-cells is 
signiﬁ  cantly reduced after successful topical treatment with 
tacrolimus. This effect is mediated by 2 major mechanisms Clinical, Cosmetic and Investigational Dermatology 2009:2 4
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directed on T-cells or keratinocytes: direct T-cell inhibition 
and Fas-mediated keratinocyte apoptosis inhibition of 
eczematous lesions.34
Therefore topical tacrolimus has strong anti-inﬂ  ammatory 
activities and a pronounced immunosuppressant potential.25,35–37
Tacrolimus ointment – clinical studies
Efﬁ  cacy – short-term studies
Efficacy of tacrolimus has been demonstrated in many 
short-term studies.
In several vehicle-controlled short-term studies, tacrolimus 
ointment, both 0.03% and 0.1%, was signiﬁ  cantly more effec-
tive than the vehicle in treating adults and children affected by 
AD, with no signiﬁ  cant differences between the two different 
concentrations.38 Tacrolimus 0.03% and 0.1% ointments have 
been compared with topical steroids. In a randomized, double-
blind study in 2- to 15-year-old children affected by moderate to 
severe AD, both concentrations showed a signiﬁ  cantly greater 
improvement than 1% hydrocortisone acetate.38,39 In adult 
patients with moderate to severe AD, tacrolimus 0.1% was as 
effective as hydrocortisone-17-butyrate, and both were superior 
to the 0.03% ointment.40 In a 3-week study in a pediatric popula-
tion, tacrolimus 0.03% ointment applied once or twice daily had 
greater efﬁ  cacy than hydrocortisone 1% acetate applied twice 
daily, even though, especially in patients with more severe 
baseline disease, double daily application of tacrolimus was 
more effective than single application.41 Even compared with 
cyclosporine, tacrolimus has been demonstrated to be superior: 
a 6-week study showed that efﬁ  cacy of 0.1% ointment was 
better than that of oral cyclosporine 3 mg/kg.42
Efﬁ  cacy – long-term studies
Efﬁ  cacy of tacrolimus ointment has been assessed in several 
thousand adult and pediatric patients in long-term, open-
label, non-comparative, multicenter studies lasting for 12 to 
48 months, in Europe and the US. In both adult and pediatric 
populations with moderate to severe AD, 0.1% tacrolimus 
ointment has showed rapid and protracted improvement 
Table 2 Principal systemic treatment for atopic dermatitis
Treatment Mechanism of action on AD Adverse effects
Corticosteroids Reduction of number and activity of lymphocites 
Reduction of inﬂ  ammatory cytokines (IL-12 and 
INF- γ)
Reduction of cyclooxygenase, platelet activating 
factor
Vasoconstriction and reduction of small vessels 
permeability
Systemic effects: hypothalamic–pituitary–adrenal axis 
suppression, reduced linear growth in children, and 
bone density changes in adults
Local effects: skin atrophy, bruising, telangiectasies, 
striae, steroid acne, hypertrichosis, tachyphylaxis, 
steroid resistance, worsening of underlying 
secondary infections
UVB-treatment Suppression of Th2 chemokine production sug-
gests that UVB exposure to the skin suppresses 
inﬁ  ltration of Th2 cells to the epidermis
Skin erythema, skin burning, risk for skin 
malignancies
Cyclosporine Inhibition of Il-2 production by blocking the 
function of the enzyme calcineurin (CaN)
Arterial hypertension, nephrotoxicity, 
and immunosuppression
Methotrexate Inhibition of synthesis of purines and pirimidines 
required for cellular proliferation of lymphocytes
Anemia, thrombopenia, gastrointestinal dysfunction, 
and pneumonitis
Antihistamines Inhibition of peripherical histamines receptors 
with reduction of vasodilatation and itching, 
inhibition of central histamines receptors with 
sedative effect, local anesthetic effect
Excessive sedation
Azathioprine Inhibition of purine synthesis with consequent 
stop in synthesis of DNA, RNA, and proteins; it 
may also interfere with cellular metabolism and 
inhibit mitosis the proliferation of cells, especially 
leukocytes
Bone marrow suppression and oncogenic potential, 
gastrointestinal symptoms. Leukopenia or infection 
fever or chills, cough or hoarseness, lower back or 
side pain, painful or difﬁ  cult urination, tiredness or 
weakness
Mycophenolate mofetil Inhibition of inosine monophosphate 
dehydrogenase (IMPDH),with following de novo 
synthesis pathway of guanosine nucleotides 
(on which T and B lymphocytes are critically 
dependent for their proliferation)
Bone marrow suppression, peripheral edema, 
arrhythmia, artralgia
TNF-α inhibitors Through inhibition of TNF-α, which has a great 
inﬂ  ammatory activity, reduction in epidermal 
hyperplasia neoangiogenesis and itching
Increased risk of infection, especially reactivation of 
tuberculosis; increased risk of lymphoproliferative 
diseases, worsening of heart failure; local reactionsClinical, Cosmetic and Investigational Dermatology 2009:2 5
Tacrolimus and atopic dermatitis
in efﬁ  cacy parameters3,43,44 Children treated with 0.03% 
ointment intermittently for 12 to 29 months and with 0.1% 
ointment periodically if the 0.03% was insufﬁ  cient, showed 
substantial improvement in efﬁ  cacy parameters, including 
pruritus within 2 weeks, and maintained the result throughout 
the study.45
A multicenter, randomized, double-blind, controlled 
study of 6 months compared tacrolimus ointment 0.1% on 
the trunk and extremities with hydrocortisone-17-butyrate 
and on the face and neck with 1% hydrocortisone acetate in 
an adult population with moderate to severe AD. Tacrolimus 
achieved greater improvement in all efﬁ  cacy parameters, and 
a higher percentage of the patients showed at least a 60% 
response (72.6% vs 52.3%, p  0.001).46
Tacrolimus and safety
Safety of tacrolimus ointment has been demonstrated in 
short- and especially long-term studies, as it has been dem-
onstrated that systemic absorption of tacrolimus from topical 
application is largely minimal. Topical treatment can lead to 
blood concentrations of a maximum of approximately 3% 
of those of transplant patients using systemic tacrolimus, 
with no signs of accumulation of tacrolimus after repeated 
application.23,47,48
The most common adverse events of application of 
tacrolimus ointment (∼60% of patients) are limited to the 
site of application, such as pruritus and “skin burning”, with 
burning sensation, pain, stinging, erythema, soreness and 
ﬂ  ushes especially after alcohol ingestion.49,50 Most episodes 
of skin burning last less than 10 minutes and most episodes 
of pruritus last less than 1 hour. The prevalence of application 
site adverse events, in particular skin burning and pruritus, 
more frequent in adults than in children, is highest during 
the ﬁ  rst few days of treatment and then declines. For most 
patients who experienced an application site adverse event, 
the severity of the worst episode is mild or moderate.49
No case of skin atrophy has been reported and, moreover, 
long-term treatment with tacrolimus ointment has been 
associated with improvements in collagen synthesis and 
skin thickness.24,50
Sun avoidance is recommended during tacrolimus therapy23 
which led to black box warnings in the US on increased cancer 
risk from topical tacrolimus, despite the fact that, to date, the 
development of skin cancer as result of tacrolimus ointment 
treatment has not been reported.51
However, a recent large case-control study with a 
cohort of almost 290,000 patients receiving different AD 
treatments showed that the main factor associated with 
increased lymphoma risk is AD severity, whereas there was 
no increased risk of lymphoma in patients treated with topical 
calcineurin inhibitors.51
One of the most discussed adverse effects of topical 
tacrolimus was the increase of infections but most of these 
are considered mild or moderate in severity and were not 
conﬁ  rmed by the study investigators to be related to the use 
of tacrolimus ointment.49 Nevertheless there is no evidence of 
an increase in the risk of cutaneous infections with long-term 
use of tacrolimus ointment, and the incidence of cutaneous 
infections in the long-term studies is comparable with that 
observed with 12-week application.52
No clinically meaningful changes in mean or median 
values for hematology, indicators of hepatic or renal func-
tion, serum electrolytes, blood glucose and serum IgE have 
been observed.49
According to a recent systemic review on topical treat-
ment of AD, signiﬁ  cant local or systemic adverse events are 
mainly associated with use of topical corticosteroids.53
These ﬁ  ndings suggest that tacrolimus ointment may be a 
better choice for long-term treatment to control and prevent 
AD ﬂ  ares in all patients, including children.30
Topical tacrolimus in practice
AD is a disease resulting from the interaction of genetic, 
environmental and immunological factors and presents many 
clinical aspects.30 Therefore, patients suffering from AD 
require individual management.
Many studies have demonstrated that tacrolimus ointment 
is effective for the treatment of AD.54,55 Tacrolimus ointment 
is suitable for the short and intermittent long-term treat-
ment of moderate to severe AD in patients over 24 months 
old who are not adequately responsive or are intolerant to 
conventional therapies, such as topical corticosteroids.30,50 
A signiﬁ  cant improvement of the disease is notable within 
1 week of starting tacrolimus therapy. For adult and pediatric 
patients, the ointment should be applied at the ﬁ  rst sign of 
dry skin or pruritus. In adult patients the treatment should be 
initiated with tacrolimus 0.1% twice daily for 3 or 4 weeks; 
later on the concentration and the dosage can be reduced.30
In pediatric patients, it is advised to begin the treatment 
with tacrolimus 0.03% twice daily for 3 or 4 weeks, followed 
by once-daily application until the lesions improve.30
Potent topical corticosteroids are used reactively to treat 
AD ﬂ  ares. Unlike potent corticosteroids, tacrolimus ointment 
can be used to reduce the incidence of disease ﬂ  ares and also 
the severity of ﬂ  ares without the risk of corticosteroid-related 
adverse events.16,31,53Clinical, Cosmetic and Investigational Dermatology 2009:2 6
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Furthermore, in contrast to topical corticosteroids, 
tachyphylaxis or rebound are not observed, even in long-
term tacrolimus treatment.56 Moreover, tacrolimus ointment 
application makes the therapy of AD easy.
It is effective as monotherapy and its safety proﬁ  le enables 
its use on all affected areas of the body (including face, neck 
and fold sites) for as long as necessary, without the need for 
concomitant corticosteroid therapy.57 This is one of the most 
important differences between tacrolimus and topical corti-
costeroid regimens routinely used. In fact, topical steroids 
therapy includes a less potent preparation on sensitive skin 
areas and a more potent preparation on other affected areas 
for a short time to diminish adverse-related effects.40,58,59
Although tacrolimus has potent immunosuppressive 
ability, it does not seem to increase Staphylococcus aureus 
colonization, probably because of its healing effects on the 
skin, which can reduce the ability of adhesion molecules 
necessary for staphylococcal colonization.60,61
No studies have reported signiﬁ  cant enhancement of viral 
or bacterial infections in patients treated with tacrolimus 
ointment.43,62
It is important to advise patients using tacrolimus ointment 
to avoid a solarium, to minimize exposure to sunlight, and 
to use sunscreen, even though it is not a photo-sensitizer.23 
Moreover the risk of photo-carcinogenicity with topical 
tacrolimus is small in clinical practice.30,63–65
In conclusion, 0.03% and 0.1% tacrolimus ointment can 
be used daily for periods of up to 1 year for AD treatment in 
patients, including padiatric patients, without increasing the 
risk of infection or other non-application site adverse events, 
and without loss of effectiveness.47,57
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